Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Veracyte, Inc. (VCYT : NSDQ)
 
 • Company Description   
Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California.

Number of Employees: 824

 
 • Price / Volume Information   
Yesterday's Closing Price: $27.58 Daily Weekly Monthly
20 Day Moving Average: 993,996 shares
Shares Outstanding: 78.32 (millions)
Market Capitalization: $2,159.92 (millions)
Beta: 2.07
52 Week High: $47.32
52 Week Low: $19.73
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 1.06% -3.10%
12 Week -15.45% -25.91%
Year To Date -30.35% -34.22%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
6000 SHORELINE COURT SUITE 300
-
SOUTH SAN FRANCISCO,CA 94080
USA		 ph: 650-243-6300
fax: 650-243-6301		 investors@veracyte.com http://www.veracyte.com
 
 • General Corporate Information   
Officers
Marc Stapley - Chief Executive Officer and Director
Robert S. Epstein - Chairperson and Director
Rebecca Chambers - Chief Financial Officer
Eliav Barr - Director
Muna Bhanji - Director

Peer Information
Veracyte, Inc. (ABMD)
Veracyte, Inc. (DMDS)
Veracyte, Inc. (CPWY.)
Veracyte, Inc. (EQUR)
Veracyte, Inc. (ECIA)
Veracyte, Inc. (FMS)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 92337F107
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/05/25
Share - Related Items
Shares Outstanding: 78.32
Most Recent Split Date: (:1)
Beta: 2.07
Market Capitalization: $2,159.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.20 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $0.81 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 34.15
Trailing 12 Months: 30.31
PEG Ratio: -
Price Ratios
Price/Book: 1.81
Price/Cash Flow: 26.60
Price / Sales: 4.66
EPS Growth
vs. Year Ago Period: 1,000.00%
vs. Previous Quarter: -25.00%
Sales Growth
vs. Year Ago Period: 18.20%
vs. Previous Quarter: -3.51%
ROE
06/30/25 - -
03/31/25 - 6.14
12/31/24 - 4.87
ROA
06/30/25 - -
03/31/25 - 5.60
12/31/24 - 4.47
Current Ratio
06/30/25 - -
03/31/25 - 5.10
12/31/24 - 4.73
Quick Ratio
06/30/25 - -
03/31/25 - 4.78
12/31/24 - 4.46
Operating Margin
06/30/25 - -
03/31/25 - 15.50
12/31/24 - 12.57
Net Margin
06/30/25 - -
03/31/25 - 7.13
12/31/24 - 5.41
Pre-Tax Margin
06/30/25 - -
03/31/25 - 7.57
12/31/24 - 5.78
Book Value
06/30/25 - -
03/31/25 - 15.26
12/31/24 - 15.17
Inventory Turnover
06/30/25 - -
03/31/25 - 6.92
12/31/24 - 7.41
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©